Alpha-1-proteinase inhibitor
- Generic Name
- Alpha-1-proteinase inhibitor
- Brand Names
- Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9041-92-3
- Unique Ingredient Identifier
- F43I396OIS
- Background
Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
- Indication
For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
- Associated Conditions
- Emphysema
- Associated Therapies
- Augmentation, Maintenance therapy
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT05856331
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Blessing Corporate Services, Inc
- Registration Number
- NCT04675086
- Locations
- 🇺🇸
Blessing Corporate Services, Inc, Hannibal, Missouri, United States
Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04204252
- Locations
- 🇸🇪
Skåne University Hospital, Malmö, Sweden
🇳🇱Leiden University Medical Center (LUMC), Leiden, ZA, Netherlands
🇫🇮Tays Central Hospital, Tampere, Finland
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- John Levine
- Target Recruit Count
- 30
- Registration Number
- NCT03459040
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Octapharma
- Registration Number
- NCT03385395
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Impatients N.V. trading as myTomorrows
- Registration Number
- NCT03172455
Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 48
- Registration Number
- NCT02947087
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Anti-inflammatory Therapy to Improve Outcomes After TPIAT
- Conditions
- Interventions
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT02713997
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02464878
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02191839
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.